Loading...

resTORbio

Nasdaq:TORC
Snowflake Description

Flawless balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
TORC
Nasdaq
$274M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

resTORbio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. The last earnings update was 39 days ago. More info.


Add to Portfolio Compare Print
TORC Share Price and Events
7 Day Returns
12.2%
NasdaqGS:TORC
-0.9%
US Pharmaceuticals
0.9%
US Market
1 Year Returns
-15.2%
NasdaqGS:TORC
8.5%
US Pharmaceuticals
9.6%
US Market
TORC Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
resTORbio (TORC) 12.2% 7.4% -8.9% -15.2% - -
US Pharmaceuticals -0.9% -3.7% 0.2% 8.5% 8.3% 14.3%
US Market 0.9% 4.6% 10.9% 9.6% 39% 47.2%
1 Year Return vs Industry and Market
  • TORC underperformed the Pharmaceuticals industry which returned 8.5% over the past year.
  • TORC underperformed the Market in United States of America which returned 9.6% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

TORC Value

 Is resTORbio undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of resTORbio to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for resTORbio.

NasdaqGS:TORC Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 3 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.5%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGS:TORC
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.68
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.676 (1 + (1- 21%) (0%))
0.783
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.8 * 5.96%)
7.5%

Discounted Cash Flow Calculation for NasdaqGS:TORC using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for resTORbio is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqGS:TORC DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.5%)
2019 -78.00 Analyst x1 -72.56
2020 -90.00 Analyst x1 -77.88
2021 -104.00 Analyst x1 -83.72
2022 38.00 Analyst x1 28.46
2023 162.00 Analyst x1 112.85
2024 169.10 Est @ 4.38% 109.58
2025 175.67 Est @ 3.89% 105.90
2026 181.89 Est @ 3.54% 102.00
2027 187.89 Est @ 3.3% 98.02
2028 193.77 Est @ 3.13% 94.03
Present value of next 10 years cash flows $416.68
NasdaqGS:TORC DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $193.77 × (1 + 2.73%) ÷ (7.5% – 2.73%)
$4,174.83
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $4,174.83 ÷ (1 + 7.5%)10
$2,025.98
NasdaqGS:TORC Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $416.68 + $2,025.98
$2,442.66
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $2,442.66 / 36.34
$67.23
NasdaqGS:TORC Discount to Share Price
Calculation Result
Value per share (USD) From above. $67.23
Current discount Discount to share price of $7.54
= -1 x ($7.54 - $67.23) / $67.23
88.8%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price resTORbio is available for.
Intrinsic value
>50%
Share price is $7.54 vs Future cash flow value of $67.23
Current Discount Checks
For resTORbio to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • resTORbio's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • resTORbio's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for resTORbio's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are resTORbio's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:TORC PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.42
NasdaqGS:TORC Share Price ** NasdaqGS (2019-04-25) in USD $7.54
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 29 Publicly-Listed Pharmaceuticals Companies 18.77x
United States of America Market PE Ratio Median Figure of 3,081 Publicly-Listed Companies 18.28x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of resTORbio.

NasdaqGS:TORC PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:TORC Share Price ÷ EPS (both in USD)

= 7.54 ÷ -1.42

-5.3x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • resTORbio is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • resTORbio is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does resTORbio's expected growth come at a high price?
Raw Data
NasdaqGS:TORC PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -5.3x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
35.7%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 23 Publicly-Listed Pharmaceuticals Companies 1.51x
United States of America Market PEG Ratio Median Figure of 2,113 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for resTORbio, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on resTORbio's assets?
Raw Data
NasdaqGS:TORC PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $3.71
NasdaqGS:TORC Share Price * NasdaqGS (2019-04-25) in USD $7.54
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 183 Publicly-Listed Pharmaceuticals Companies 3.52x
United States of America Market PB Ratio Median Figure of 5,185 Publicly-Listed Companies 1.92x
NasdaqGS:TORC PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:TORC Share Price ÷ Book Value per Share (both in USD)

= 7.54 ÷ 3.71

2.03x

* Primary Listing of resTORbio.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • resTORbio is good value based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess resTORbio's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. resTORbio has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

TORC Future Performance

 How is resTORbio expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
35.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is resTORbio expected to grow at an attractive rate?
  • resTORbio's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • resTORbio's earnings growth is expected to exceed the United States of America market average.
  • Unable to compare resTORbio's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:TORC Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:TORC Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 35.7%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 18.6%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.5%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:TORC Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:TORC Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 406 200 2
2022-12-31 160 55 2
2021-12-31 25 -102 2
2020-12-31 0 -90 2
2019-12-31 0 -64 2
NasdaqGS:TORC Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -36 -38
2018-09-30 -33 -55
2018-06-30 -26 -50
2018-03-31 -18 -40
2017-12-31 -11 -34
2016-12-31 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • resTORbio's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if resTORbio is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:TORC Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from resTORbio Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:TORC Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 2.53 4.06 0.99 2.00
2022-12-31 -0.14 1.13 -1.40 2.00
2021-12-31 -2.34 -1.97 -2.70 2.00
2020-12-31 -2.59 -2.28 -2.97 3.00
2019-12-31 -1.97 -1.66 -2.20 3.00
NasdaqGS:TORC Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.42
2018-09-30 -2.67
2018-06-30 -3.40
2018-03-31 -4.63
2017-12-31 -8.42
2016-12-31

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if resTORbio will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess resTORbio's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
resTORbio has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

TORC Past Performance

  How has resTORbio performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare resTORbio's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • resTORbio does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare resTORbio's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare resTORbio's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
resTORbio's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from resTORbio Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:TORC Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -37.61 8.64 31.07
2018-09-30 -54.91 7.36 33.51
2018-06-30 -49.81 5.71 30.08
2018-03-31 -40.28 4.07 21.65
2017-12-31 -33.78 2.04 16.84
2016-12-31 0.00 0.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if resTORbio has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if resTORbio has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if resTORbio improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess resTORbio's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
resTORbio has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

TORC Health

 How is resTORbio's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up resTORbio's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • resTORbio is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • resTORbio's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of resTORbio's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • resTORbio has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from resTORbio Company Filings, last reported 3 months ago.

NasdaqGS:TORC Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 104.20 0.00 108.03
2018-09-30 109.34 0.00 115.38
2018-06-30 117.16 0.00 125.92
2018-03-31 130.38 0.00 135.71
2017-12-31 49.69 0.00 53.35
2016-12-31 0.00 0.00
  • resTORbio has no debt.
  • resTORbio has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • resTORbio has sufficient cash runway for more than 3 years based on current free cash flow.
  • resTORbio has sufficient cash runway for 2 years if free cash flow continues to grow at historical rates of 91.2% each year.
X
Financial health checks
We assess resTORbio's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. resTORbio has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

TORC Dividends

 What is resTORbio's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from resTORbio dividends. Estimated to be 0% next year.
If you bought $2,000 of resTORbio shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate resTORbio's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate resTORbio's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:TORC Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 2.8%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2008 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:TORC Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as resTORbio has not reported any payouts.
  • Unable to verify if resTORbio's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of resTORbio's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as resTORbio has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of resTORbio's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess resTORbio's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can resTORbio afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. resTORbio has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

TORC Management

 What is the CEO of resTORbio's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Chen Schor
COMPENSATION $3,094,901
AGE 46
TENURE AS CEO 2.8 years
CEO Bio

Mr. Chen Schor, MBA, CPA, BA, CPA, is a Co-Founder of resTORbio, Inc. and serves as its President and Chief Executive Officer since incorporation in July 2016. Mr. Schor serves as Chief Business Officer at Follica, Inc. He has over 15 years of leadership experience in biotechnology, medical devices, business development and private equity. He served as the Chief Executive Officer, President and Director at Synta Pharmaceuticals Corp. since May 7, 2015 and served as its Chief Operating Officer and Executive Vice President from December 08, 2014 to May 7, 2015. Mr. Schor served as the President and Chief Executive Officer at Novalere FP, Inc. (Novalere, Inc.). He served as the Chief Business Officer of Eleven Biotherapeutics Inc. Mr. Schor joined Eleven Biotherapeutics on September 22, 2011. He served as the Chief Business Officer and Senior Vice President of Predix Pharmaceuticals Holdings, Inc. He served as the Chief Business Officer of EPIX Pharmaceuticals, Inc. from August 16, 2006 to March 23, 2009. Mr. Schor served as the Chief Business Officer of Predix Pharmaceuticals, Inc. from January 2004 to August 2006 and also served as its Senior Vice President. From 1998 to December 2003, he served as a Partner, Life Sciences at The Yozma Group (Yozma Venture Capital Group) and also served as its Principal and Chief Financial Officer. He served as a Vice President of Business Development, Global Branded Products of Teva Pharmaceutical Industries Limited and served as its Vice President of Global Branded Business Development and Pipeline Management. Mr. Schor led strategic transactions valued at over $8 billion with companies such as GSK, Amgen, Pfizer, Merck KGaA (co-led) and Cephalon (co-led). Mr. Schor was actively involved in evaluating Yozma's Medical Technologies, Bio-Informatics and Biotechnology investment opportunities. Mr. Schor leads corporate and business development initiatives including oversight and establishment of strategic collaborations for EPIX programs and assets and strategic planning activities. He also served at ESC Medical, Elbit and Elscint. He held positions at BDO consultants from 1996 to 1998. He has vast experience leading biotech companies across all stages, from formation, building a team and early stage discovery to a publicly traded multi-product company with significant big pharma partnerships. He serves as a Director of Novalere FP, Inc. (Novalere, Inc.). He serves as a Director of resTORbio, Inc. since July 2016. He has been a Director of Brainstorm Cell Therapeutics Inc., since August 22, 2011. Mr. Schor served as an Auditor of Arthur Andersen & Co. from 1995 to 1996. He served as a Director at Can-Fite BioPharma Ltd. since 1998. He served as a Director of Gelesis, Inc. He served as a Director of Predix Pharmaceuticals Holdings Inc. from August 2003 to December 2003. He served as a Member of the Board of directors of Predix Pharmaceuticals Ltd. from November 2000 to August 2003 and Predix Pharmaceuticals, Inc. from September 2001 to August 2003. Mr. Schor is a Certified Public Accountant. He holds B.A. in Economics and Accounting from Haifa University and a B.A. in Biology from Tel Aviv University and an M.B.A. Degree from Tel Aviv University.

CEO Compensation
  • Chen's compensation has increased whilst company is loss making.
  • Chen's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the resTORbio management team in years:

1.9
Average Tenure
50
Average Age
  • The average tenure for the resTORbio management team is less than 2 years, this suggests a new team.
Management Team

Chen Schor

TITLE
Co-Founder
COMPENSATION
$3M
AGE
46
TENURE
2.8 yrs

Joan Mannick

TITLE
Co-Founder & Chief Medical Officer
COMPENSATION
$1M
AGE
59

Meredith Manning

TITLE
Chief Commercial Officer
COMPENSATION
$2M
AGE
46
TENURE
0.6 yrs

John McCabe

TITLE
Vice President of Finance
COMPENSATION
$549K
AGE
50
TENURE
1.5 yrs

Jennifer Robinson

TITLE
Senior Director of Investor Relations & Corporate Communication

Abdellah Sentissi

TITLE
Head of CMC & Pharmaceutical Development
AGE
68
TENURE
2.3 yrs

Sue Stewart

TITLE
Head of Regulatory Affairs
Board of Directors Tenure

Average tenure and age of the resTORbio board of directors in years:

1.2
Average Tenure
51.5
Average Age
  • The average tenure for the resTORbio board of directors is less than 3 years, this suggests a new board.
Board of Directors

Chen Schor

TITLE
Co-Founder
COMPENSATION
$3M
AGE
46
TENURE
2.8 yrs

Paul Fonteyne

TITLE
Director
COMPENSATION
$260K
AGE
56
TENURE
1.3 yrs

Jonathan Silverstein

TITLE
Director
COMPENSATION
$40K
AGE
51
TENURE
1.4 yrs

Lynne Sullivan

TITLE
Director
COMPENSATION
$255K
AGE
52
TENURE
1.3 yrs

David Steinberg

TITLE
Director
COMPENSATION
$42K
AGE
46
TENURE
2.1 yrs

Frederick Hayden

TITLE
Member of Clinical Advisory Board
TENURE
1.1 yrs

Sebastian Johnston

TITLE
Member of Clinical Advisory Board
TENURE
1.1 yrs

Janet McElhaney

TITLE
Member of Clinical Advisory Board
TENURE
1.1 yrs

Richard Whitley

TITLE
Member of Clinical Advisory Board
TENURE
1.1 yrs

Jeff Chodakewitz

TITLE
Non-Employee Director
COMPENSATION
$241K
AGE
62
TENURE
0.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess resTORbio's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. resTORbio has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

TORC News

Simply Wall St News

resTORbio Inc's (NASDAQ:TORC) Profit Outlook

The US$261.67m market-cap posted a loss in its most recent financial year of -US$33.78m and a latest trailing-twelve-month loss of -US$40.28m leading to an even wider gap between loss and breakeven? … The most pressing concern for investors is TORC’s path to profitability – when will it breakeven

Simply Wall St -

What You Must Know About resTORbio Inc's (NASDAQ:TORC) Major Investors

This size of ownership gives retail investors collective power in deciding on major policy decisions such as executive compensation, appointment of directors and acquisitions of businesses. … This level of ownership gives retail investors the power to sway key policy decisions such as board composition, executive compensation, and potential acquisitions. … Thus, investors should dig deeper into TORC's business relations with these companies and how it can affect shareholder returns in the long-term.Next Steps: With a low level of institutional ownership, investors in TORC need not worry about non-fundamental factors such as ownership structure causing large impact on stock prices.

Simply Wall St -

resTORbio Inc (NASDAQ:TORC): Is Healthcare An Attractive Sector Play?

Not surprisingly, this rate is more than double the growth rate of the US stock market as a whole. … This means it is an attractive growth stock relative to the wider US stock market. … Pharmaceutical companies are typically trading at a PE of 24.2x, relatively similar to the rest of the US stock market PE of 19.9x.

Simply Wall St -

TORC Company Info

Description

resTORbio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. Its lead program is targeting the selective inhibitor of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems. The company’s lead drug candidate RTB101 is an orally administered, TORC1 inhibitor, which completed Phase 2b clinical trial as a first in-class immunotherapy for reducing the incidence of respiratory tract infections in the elderly by enhancing the function of the immune system. It also intends to develop RTB101 for additional aging-related indications, such as urinary tract infections, neurodegenerative diseases, and heart failure. The company was founded in 2016 and is headquartered in Boston, Massachusetts.

Details
Name: resTORbio, Inc.
TORC
Exchange: NasdaqGS
Founded: 2016
$273,968,493
36,335,344
Website: http://www.restorbio.com
Address: resTORbio, Inc.
500 Boylston Street,
12th floor,
Boston,
Massachusetts, 02116,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS TORC Common Stock Nasdaq Global Select US USD 26. Jan 2018
DB 1IJ Common Stock Deutsche Boerse AG DE EUR 26. Jan 2018
LSE 0HX7 Common Stock London Stock Exchange GB USD 26. Jan 2018
Number of employees
Current staff
Staff numbers
21
resTORbio employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/26 03:25
End of day share price update: 2019/04/25 00:00
Last estimates confirmation: 2019/03/29
Last earnings filing: 2019/03/18
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.